Clinical Trial Update: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies [Phase 1]

View source ↗

Summary

Clinical Trial Update reports the termination of a Phase 1 study of TG-1701 in B-cell malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• TG-1701

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED